Sequoia Vaccines, Inc
Sequoia Vaccines, Inc. is a privately held, clinical-stage pharmaceutical company developing a three-program pipeline (SEQ-400 FimH vaccine for recurrent UTIs, SEQ-1274 small molecules for ovarian/uterine cancer, and a CF lung-infection small-molecule platform) for patients affected by antimicrobial-resistant infections and gynecologic cancers.
- Company typePrivate
- Founded2012
- HeadquartersSt Louis, United States
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sequoia Vaccines, Inc does
Sequoia Vaccines, Inc. is a privately held, clinical-stage pharmaceutical company advancing a three-program pipeline of vaccine and small-molecule therapeutics. The portfolio is anchored by SEQ-400, a FimH-based vaccine designed to prevent recurrent urinary tract infections as a non-antibiotic alternative, an area situated at the intersection of unmet medical need and the public-health priority around antimicrobial resistance. A second program, SEQ-1274, is a small-molecule platform targeting ovarian and uterine cancer, while a third undisclosed-structure small-molecule platform is directed at cystic fibrosis lung infections. The technology base spans FimH adhesin-based vaccinology and proprietary small-molecule chemistry across infectious disease and oncology indications.
The pipeline addresses three distinct patient populations: women with recurrent UTIs, patients with gynecologic malignancies, and individuals with cystic fibrosis experiencing chronic pulmonary infections. Each program targets a therapeutic area where existing standard of care is either antibiotic-dependent (contributing to AMR), sub-optimal in efficacy, or both. The disclosed leadership group has more than 100 years of combined experience and is supported by a scientific advisory board, although specific credentials are not enumerated in the available data.
As a clinical-stage entity with no disclosed approvals, partnerships, or commercial sales, Sequoia Vaccines' business model is pre-commercial. Value creation is expected to derive from advancing assets through clinical milestones, securing regulatory designations (e.g., FDA priority review, breakthrough, or orphan pathways, particularly under AMR-focused STEDI principles), and eventually out-licensing, partnering, or directly commercializing approved products. No pricing, manufacturing, or go-to-market mechanics are disclosed at this stage.
Sequoia Vaccines, Inc firmographics
Firmographics- Name
- Sequoia Vaccines, Inc
- Legal name
- Sequoia Vaccines, Inc.
- Website
- https://sequoiasciences.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Short description
- Sequoia Vaccines, Inc. is a privately held, clinical-stage pharmaceutical company developing a three-program pipeline (SEQ-400 FimH vaccine for recurrent UTIs, SEQ-1274 small molecules for ovarian/uterine cancer, and a CF lung-infection small-molecule platform) for patients affected by antimicrobial-resistant infections and gynecologic cancers.
- Ownership category
- akta.pro rank
Sequoia Vaccines, Inc industry classification
Industry- Product category
- Clinical-Stage Vaccine & Small-Molecule Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro industry
- Therapeutic Vaccines (e.g., Cancer/Chronic Infection)Infectious Disease & Antimicrobials Pharmaceuticals
Keywords
Where Sequoia Vaccines, Inc is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Markets served
Sequoia Vaccines, Inc business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Sequoia Vaccines, Inc product offering
Product offeringCore offering
Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company developing a three-program pipeline: SEQ-400, a FimH-based vaccine for the prevention of recurrent urinary tract infections; the SEQ-1274 small-molecule drug platform for the treatment of ovarian, uterine, and other cancers; and a novel small-molecule drug platform for treating lung infections associated with cystic fibrosis. The portfolio combines vaccine and small-molecule approaches targeting antimicrobial resistance and gynecological cancers.
Product overview
Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company with a three-program product pipeline. The portfolio includes SEQ-400, a FimH vaccine for preventing recurrent UTIs; the SEQ-1274 small-molecule platform targeting ovarian and uterine cancers; and a novel small-molecule drug platform for treating lung infections in cystic fibrosis patients. These programs collectively address antimicrobial resistance and cancer.
Differentiator
Problem solved
Functional benefit
Products and services
- SEQ-400 SEQ-400 is a FimH vaccine candidate under clinical-stage development for the prevention of recurrent urinary tract infections. FimH is a bacterial adhesin protein found on the surface of uropathogenic E. coli, and the vaccine is intended to interrupt bacterial adhesion, reducing rUTI recurrence and antibiotic dependency.
- SEQ-1274 Drug Platform SEQ-1274 is a small-molecule oncology drug platform generating candidates for the treatment of ovarian, uterine, and other cancers. The platform is designed to deliver small-molecule therapeutics intended for gynecological and broader oncology indications.
- Novel Small Molecule Drug Platform for Cystic Fibrosis A drug platform composed of novel small-molecule lead compounds being optimized for the treatment of bacterial lung infections in cystic fibrosis patients, targeting chronic and biofilm-associated infections in the CF lung.
Companies that use Sequoia Vaccines, Inc
Customer profileSegments3 records
Ideal customer profiles3 records
Sequoia Vaccines, Inc technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Sequoia Vaccines, Inc partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights3 records
Sequoia Vaccines, Inc competitors and assessment
Company assessmentBroad incumbents
- BioNTech: Global vaccine and immuno-oncology company with mRNA and protein-based vaccine platforms addressing infectious disease and oncology. Comparable in modality (vaccines) and oncology adjacency to Sequoia's small-molecule and vaccine programs.
- Pfizer: Global pharmaceutical incumbent with both vaccine and oncology franchises (Prevnar, oncology portfolio). Comparable as a benchmark for vaccine manufacturing, regulatory navigation, and oncology small-molecule development that Sequoia would need to compete against or partner with.
- Moderna: Established vaccine biotech with a broad mRNA and protein-subunit vaccine pipeline, including infectious disease programs. Comparable as a large-scale vaccine platform operator; Sequoia is a much smaller, narrowly focused peer in the vaccine technology space.
- Vertex Pharmaceuticals: Dominant commercial-stage CF therapeutics company. Comparable because Sequoia's third program targets bacterial lung infections in CF patients — same patient population and treatment setting, though Vertex's portfolio is much broader and later stage.
- GlaxoSmithKline: Major vaccine and pharmaceutical company with a broad infectious-disease vaccine franchise and growing oncology pipeline. Comparable in scope of vaccine and oncology operations relevant to Sequoia's multi-platform strategy.
Emerging players
- Innovation Pharmaceuticals: Clinical-stage biopharmaceutical company developing novel small-molecule and biologic therapies, including anti-infectives. Comparable as a small clinical-stage peer with multi-program pipeline across infectious disease and oncology.
- Aprea Therapeutics: Clinical-stage small-molecule oncology company developing targeted therapies for cancer indications with high unmet need. Comparable in being a small private/clinical-stage biotech with a small-molecule platform addressing oncology indications similar to Sequoia's SEQ-1274 program.
- Novavax: Clinical-to-commercial vaccine biotech using protein-subunit and nanoparticle vaccine platforms. Comparable to Sequoia in relying on recombinant protein-subunit vaccine technology, though at a much later development stage and broader indication scope.
- VBI Vaccines: Clinical-stage vaccine company developing immunotherapies and infectious-disease vaccines using enveloped virus-like particle and protein-subunit platforms. Comparable as a small-cap clinical-stage vaccine peer pursuing indications with limited current standard of care.
Direct peers
- OM Pharma: Swiss specialty pharma that markets Uro-Vaxom, an immune-stimulating bacterial therapy indicated for prevention of recurrent UTIs. Directly comparable as the only commercial-stage product addressing the same rUTI prevention indication Sequoia's SEQ-400 targets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights4 records
Customer concentration
Sequoia Vaccines, Inc social profiles
Digital presenceSequoia Vaccines, Inc financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sequoia Vaccines, Inc leadership team
Management profileNumber of profiles
Sequoia Vaccines, Inc funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sequoia Vaccines, Inc M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sequoia Vaccines, Inc
What does Sequoia Vaccines, Inc do?
Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company developing a three-program pipeline: SEQ-400, a FimH-based vaccine for the prevention of recurrent urinary tract infections; the SEQ-1274 small-molecule drug platform for the treatment of ovarian, uterine, and other cancers; and a novel small-molecule drug platform for treating lung infections associated with cystic fibrosis. The portfolio combines vaccine and small-molecule approaches targeting antimicrobial resistance and gynecological cancers.
Is Sequoia Vaccines, Inc a public or private company?
Sequoia Vaccines, Inc is a private company. It is classified as unknown and is currently operating.
When was Sequoia Vaccines, Inc founded?
Sequoia Vaccines, Inc was founded in 2012.
Where is Sequoia Vaccines, Inc based?
Sequoia Vaccines, Inc is headquartered in St Louis, United States, in the North America region.
Who are Sequoia Vaccines, Inc's main competitors?
Broad incumbents on record are BioNTech, Pfizer, Moderna, Vertex Pharmaceuticals and GlaxoSmithKline. Emerging players are Innovation Pharmaceuticals, Aprea Therapeutics, Novavax and VBI Vaccines. OM Pharma is listed as a direct peer.
Does Sequoia Vaccines, Inc have an API?
No public API is recorded for Sequoia Vaccines, Inc.
What industry is Sequoia Vaccines, Inc in?
Sequoia Vaccines, Inc's product category is Clinical-Stage Vaccine & Small-Molecule Therapeutics. Its primary akta.pro industry code is HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection), with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.